# A Study of SRSD107 in Participants With Chronic Coronary and/or Peripheral Arterial Disease

> **NCT07318155** · PHASE2 · RECRUITING · sponsor: **Sirius Therapeutics Co., Ltd.** · enrollment: 104 (estimated)

## Conditions studied

- Coronary Artery Disease (CAD)
- Peripheral Arterial Disease

## Interventions

- **DRUG:** SRSD107
- **DRUG:** 0.9 % sodium chloride

## Key facts

- **NCT ID:** NCT07318155
- **Lead sponsor:** Sirius Therapeutics Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-11
- **Primary completion:** 2027-12
- **Final completion:** 2028-12
- **Target enrollment:** 104 (ESTIMATED)
- **Last updated:** 2026-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07318155

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07318155, "A Study of SRSD107 in Participants With Chronic Coronary and/or Peripheral Arterial Disease". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT07318155. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*